| BPC-157 | Body Protection Compound 157 |
| ADME | Absorption, Distribution, Metabolism, and Excretion |
| BCS | Biopharmaceutical Classification System |
| PK | Pharmacokinetics |
| PD | Pharmacodynamics |
| PK/PD | Pharmacokinetic–Pharmacodynamic |
| VEGF | Vascular Endothelial Growth Factor |
| VEGFR2 | Vascular Endothelial Growth Factor Receptor 2 |
| Egr-1 | Early Growth Response 1 |
| NO | Nitric Oxide |
| eNOS | Endothelial Nitric Oxide Synthase |
| HO-1 | Heme Oxygenase-1 |
| TNF-α | Tumor Necrosis Factor Alpha |
| IL | Interleukin |
| NF-κB | Nuclear Factor Kappa B |
| LC-MS/MS | Liquid Chromatography–Tandem Mass Spectrometry |
| Cmax | Maximum Plasma Concentration |
| AUC | Area Under the Curve |
| IM | Intramuscular |
| IV | Intravenous |
| SC | Subcutaneous |
| CNS | Central Nervous System |
| PLGA | Poly(lactic-co-glycolic acid) |
| SNAC | Sodium N-[8-(2-hydroxybenzoyl)amino]caprylate |
| ICH | International Council for Harmonisation |
| FDA | Food and Drug Administration |
| EMA | European Medicines Agency |
| WADA | World Anti-Doping Agency |
| cGMP | Current Good Manufacturing Practice |
| GLP | Good Laboratory Practice |